94 related articles for article (PubMed ID: 31501528)
1. Role for kappa-opioid system in stress-induced cocaine use uncovered with PET.
Blevins D; Martinez D
Neuropsychopharmacology; 2020 Jan; 45(1):233-234. PubMed ID: 31501528
[No Abstract] [Full Text] [Related]
2. Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study.
Martinez D; Slifstein M; Matuskey D; Nabulsi N; Zheng MQ; Lin SF; Ropchan J; Urban N; Grassetti A; Chang D; Salling M; Foltin R; Carson RE; Huang Y
Neuropsychopharmacology; 2019 Sep; 44(10):1720-1727. PubMed ID: 31026862
[TBL] [Abstract][Full Text] [Related]
3. Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging.
Placzek MS; Schroeder FA; Che T; Wey HY; Neelamegam R; Wang C; Roth BL; Hooker JM
ACS Chem Neurosci; 2019 Jan; 10(1):384-395. PubMed ID: 30212182
[TBL] [Abstract][Full Text] [Related]
4. Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine.
Chefer VI; Morón JA; Hope B; Rea W; Shippenberg TS
Neuroscience; 2000; 101(3):619-27. PubMed ID: 11113311
[TBL] [Abstract][Full Text] [Related]
5. Kappa agonist-induced reinstatement of cocaine seeking in squirrel monkeys: a role for opioid and stress-related mechanisms.
Valdez GR; Platt DM; Rowlett JK; Rüedi-Bettschen D; Spealman RD
J Pharmacol Exp Ther; 2007 Nov; 323(2):525-33. PubMed ID: 17702903
[TBL] [Abstract][Full Text] [Related]
6. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.
Bidlack JM
Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983
[TBL] [Abstract][Full Text] [Related]
7. Preprodynorphin mediates locomotion and D2 dopamine and mu-opioid receptor changes induced by chronic 'binge' cocaine administration.
Bailey A; Yoo JH; Racz I; Zimmer A; Kitchen I
J Neurochem; 2007 Sep; 102(6):1817-1830. PubMed ID: 17532787
[TBL] [Abstract][Full Text] [Related]
8. Determination of in vivo Bmax and Kd for 11C-GR103545, an agonist PET tracer for κ-opioid receptors: a study in nonhuman primates.
Tomasi G; Nabulsi N; Zheng MQ; Weinzimmer D; Ropchan J; Blumberg L; Brown-Proctor C; Ding YS; Carson RE; Huang Y
J Nucl Med; 2013 Apr; 54(4):600-8. PubMed ID: 23424192
[TBL] [Abstract][Full Text] [Related]
9. Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593.
Schenk S; Partridge B; Shippenberg TS
Psychopharmacology (Berl); 2000 Jul; 151(1):85-90. PubMed ID: 10958121
[TBL] [Abstract][Full Text] [Related]
10. Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.
Placzek MS; Van de Bittner GC; Wey HY; Lukas SE; Hooker JM
Neuropsychopharmacology; 2015 Dec; 40(13):2865-72. PubMed ID: 26058662
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior.
Váradi A; Marrone GF; Eans SO; Ganno ML; Subrath JJ; Le Rouzic V; Hunkele A; Pasternak GW; McLaughlin JP; Majumdar S
ACS Chem Neurosci; 2015 Nov; 6(11):1813-24. PubMed ID: 26325040
[TBL] [Abstract][Full Text] [Related]
12. Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans.
Walsh SL; Geter-Douglas B; Strain EC; Bigelow GE
J Pharmacol Exp Ther; 2001 Oct; 299(1):147-58. PubMed ID: 11561074
[TBL] [Abstract][Full Text] [Related]
13. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans.
Machelska H; Pflüger M; Weber W; Piranvisseh-Völk M; Daubert JD; Dehaven R; Stein C
J Pharmacol Exp Ther; 1999 Jul; 290(1):354-61. PubMed ID: 10381799
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
[TBL] [Abstract][Full Text] [Related]
15. Kappa opioid receptor binding in major depression: A pilot study.
Miller JM; Zanderigo F; Purushothaman PD; DeLorenzo C; Rubin-Falcone H; Ogden RT; Keilp J; Oquendo MA; Nabulsi N; Huang YH; Parsey RV; Carson RE; Mann JJ
Synapse; 2018 Sep; 72(9):e22042. PubMed ID: 29935119
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the kappa-opioid receptor-selective tracer [(11)C]GR103545 in awake rhesus macaques.
Schoultz BW; Hjornevik T; Willoch F; Marton J; Noda A; Murakami Y; Miyoshi S; Nishimura S; Arstad E; Drzezga A; Matsunari I; Henriksen G
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1174-80. PubMed ID: 20157708
[TBL] [Abstract][Full Text] [Related]
17. Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse.
Neumeyer JL; Mello NK; Negus SS; Bidlack JM
Pharm Acta Helv; 2000 Mar; 74(2-3):337-44. PubMed ID: 10812979
[TBL] [Abstract][Full Text] [Related]
18. Methylated analogues of methyl (R)-4-(3,4-dichlorophenylacetyl)- 3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR-89,696) as highly potent kappa-receptor agonists: stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functional studies.
Soukara S; Maier CA; Predoiu U; Ehret A; Jackisch R; Wünsch B
J Med Chem; 2001 Aug; 44(17):2814-26. PubMed ID: 11495592
[TBL] [Abstract][Full Text] [Related]
19. Arylacetamides as peripherally restricted kappa opioid receptor agonists.
Kumar V; Marella MA; Cortes-Burgos L; Chang AC; Cassel JA; Daubert JD; DeHaven RN; DeHaven-Hudkins DL; Gottshall SL; Mansson E; Maycock AL
Bioorg Med Chem Lett; 2000 Nov; 10(22):2567-70. PubMed ID: 11086731
[TBL] [Abstract][Full Text] [Related]
20. Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration.
Schenk S; Partridge B; Shippenberg TS
Neuropsychopharmacology; 2001 Apr; 24(4):441-50. PubMed ID: 11182539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
